Johnson & Johnson Reveals Updated 2023 Projections After Finalizing Biggest Shake Up In 135 Years


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


Johnson & Johnson (NYSE:JNJ) has unveiled 2023 projections, predicting double-digit profit growth after its recent spinoff of consumer health company Kenvue Inc (NYSE:KVUE). 

The company's outlook provides an early glimpse into the performance of its standalone drugs and medical device businesses.

Last week, Johnson & Johnson accepted around 190.9 million JNJ stock in exchange for around 1.5 billion Kenvue common stock.

Following the completion of the exchange offer, Johnson & Johnson retains an approximately 9.5% stake in Kenvue.

For FY2023, Johnson & Johnson anticipates adjusted reported EPS of $10 to $10.10, a 12.5% increase at the midpoint compared to 2022 and the prior guidance of $10.70–$10.80 and the consensus of $10.75.

As part of the spinoff, Johnson & Johnson intends to classify its consumer health business as discontinued operations. This move will also lead to a gain of $20 billion in Q3, further underlining the strategic and financial implications of the spinoff.

Johnson & Johnson expects FY23 reported sales growth of 7%-8% compared to previous guidance of 6.5%–7.5%.

It sees operational sales growth of 7.5%-8.5% (vs. 7%–8%) and adjusted operational sales growth of 6.2%-7.2% (compared to 6%–7%).

Price Action: JNJ shares are down 1.75% at $163.10 on the last check Wednesday.

Now Read: EXCLUSIVE: Watch Cathie Wood Predict SEC's Loss In Bitcoin ETF Case In Benzinga Interview


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareGeneralBriefs